TGFβ has been associated with NK cell dysfunction and changes in expression of activating and inhibitory receptors have been described in patients with breast cancer, melanoma, lung cancer and ovarian carcinoma [2–4, 35–38]. Here, TGFB1 is linked to melanoma.